Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.72 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.72 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.72 |
| ▸ | THRA | P10827 | 3/20 | 0.70 |
| ▸ | THRB | P10828 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | ASPH | Q12797 | 1/20 | 0.70 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724635 | 1.00 | EGLN1 (0.72) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL17945912 | 0.85 | EGLN1 (0.69) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL28861433 | 0.84 | EGLN1 (0.68) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL29390250 | 0.84 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL522744 | 0.84 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL1031799 | 0.83 | EGLN1 (0.69) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL522741 | 0.83 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| Roxadustat SCHEMBL523705 | 0.83 | THRA (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| Roxadustat SCHEMBL29892426 | 0.83 | THRA (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL523075 | 0.83 | EGLN1 (0.67) | EGLN1BBOX1FTOTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114644589-A | Preparation method of compound N- [ (4-hydroxy-1-methyl-3-isoquinolyl) carbonyl ] -glycine | 鲁南制药集团股份有限公司 | 2022-06-21 | — | — | CN | claimed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| CN-103145616-B | Nitrogen-containing heteroaryl compounds and the purposes in increase endogenous erythropoietin thereof | FIBROGEN INC. (US) | 2015-09-30 | — | — | CN | claimed |
| US-8017625-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-09-13 | — | — | US | claimed |
| EP-1644336-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN INC (US) | 2011-01-19 | — | — | EP | claimed |
| CN-101394843-A | Improved anemia treatment using HIF alpha stabilizers | FIBROGEN INC (US) | 2009-03-25 | — | — | CN | claimed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | claimed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| CN-114644589-A | Preparation method of compound N- [ (4-hydroxy-1-methyl-3-isoquinolyl) carbonyl ] -glycine | 鲁南制药集团股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114644589-A | Preparation method of compound N- [ (4-hydroxy-1-methyl-3-isoquinolyl) carbonyl ] -glycine | 鲁南制药集团股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114644589-A | Preparation method of compound N- [ (4-hydroxy-1-methyl-3-isoquinolyl) carbonyl ] -glycine | 鲁南制药集团股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9775902-B2 | Compounds and methods for treatment of stroke | FIBROGEN, INC (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3219706-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | Fibrogen, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-2872487-B1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN INC (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9339527-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| CN-105377251-A | Mobilizing agents and uses thereof | MATER MEDICAL RES INST LTD | 2016-03-02 | — | — | CN | disclosed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
| EP-2961398-A1 | MOBILIZING AGENTS AND USES THEREFOR | Mater Medical Research Institute Limited (AU) | 2016-01-06 | — | — | EP | disclosed |
| CN-103145616-B | Nitrogen-containing heteroaryl compounds and the purposes in increase endogenous erythropoietin thereof | FIBROGEN INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-102977015-B | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin | FIBROGEN INC | 2015-05-06 | — | — | CN | disclosed |
| CN-104427980-A | Treatment for high cholesterol | FIBROGEN INC | 2015-03-18 | — | — | CN | disclosed |
| US-8962530-B2 | Inflammatory bowel disease therapies | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2015-02-24 | — | — | US | disclosed |
| CN-102977016-B | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin | FIBROGEN INC | 2015-01-14 | — | — | CN | disclosed |
| US-8916585-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140343094-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2014132100-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2014-09-04 | — | — | WO | disclosed |
| US-8765956-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130310565-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2013-11-21 | — | — | US | disclosed |
| US-8530404-B2 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2013-07-11 | — | — | US | disclosed |
| US-8318703-B2 | Methods for improving kidney function | FIBROGEN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-11-08 | — | — | US | disclosed |
| US-8278325-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120149712-A1 | Methods for improving kidney function | FIBROGEN, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120029011-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8017625-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110065771-A1 | INFLAMMATORY BOWEL DISEASE THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1644336-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN INC (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7863292-B2 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100331362-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100204269-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7713986-B2 | administering an enzyme inhibitor for inhibiting hypoxia inducible factor (HIF) hydroxylase activity; who is refractory to or is at risk for being refractory to recombinant human EPO therapy | FIBROGEN, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090176726-A1 | METHODS FOR TREATING MITF-RELATED DISORDERS | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2009-07-09 | — | — | US | disclosed |
| CN-101420980-A | The Compounds and methods for of treatment apoplexy | FIBROGEN INC (US) | 2009-04-29 | — | — | CN | disclosed |
| WO-2008040002-A9 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HUTCHINSON FRED CANCER RES (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | FRED HUTCHINSON CANCER RESEARCH CENTER | 2009-01-08 | — | — | US | disclosed |
| WO-2009002533-A1 | INFLAMMATORY BOWEL DISEASE THERAPIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008040002-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | FIBROGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (30 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885BBOX1 143/4885FTO 2032/4885 |
| US-20140343094-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-20100331362-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885BBOX1 2424/4885FTO 1896/4885 |
| US-20120149712-A1 | Methods for improving kidney function | ATP6V1B1, REN, GLS | EGLN1 1174/4885BBOX1 971/4885FTO 1475/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885BBOX1 300/4885FTO 4661/4885 |
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-20100204269-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | EGLN1 25/4885BBOX1 713/4885FTO 4282/4885 |
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | HIF1A, HIF1AN, EGLN3 | EGLN1 7/4885BBOX1 879/4885FTO 2532/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885BBOX1 143/4885FTO 2032/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885BBOX1 2424/4885FTO 1896/4885 |
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | PLAT, SERPINE1, PLG | EGLN1 740/4885BBOX1 982/4885FTO 3629/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885BBOX1 143/4885FTO 2032/4885 |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | PLAT, SERPINE1, PLG | EGLN1 740/4885BBOX1 982/4885FTO 3629/4885 |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HIF1A, HIF1AN, EGLN3 | EGLN1 7/4885BBOX1 879/4885FTO 2532/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN1 21/4885BBOX1 1307/4885FTO 2512/4885 |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN2, HIF1A | EGLN1 7/4885BBOX1 206/4885FTO 2441/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | EGLN1 16/4885BBOX1 2822/4885FTO 2804/4885 |
| US-20120029011-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | TP53, MKI67, HDGF | EGLN1 98/4885BBOX1 967/4885FTO 4455/4885 |
| US-20130310565-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 160/4885FTO 2745/4885 |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN1 21/4885BBOX1 1307/4885FTO 2512/4885 |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | EGLN1 25/4885BBOX1 713/4885FTO 4282/4885 |
| US-20090176726-A1 | METHODS FOR TREATING MITF-RELATED DISORDERS | HIF1AN, HIF1A, EGLN3 | EGLN1 6/4885BBOX1 926/4885FTO 2690/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | EGLN1 7/4885BBOX1 1340/4885FTO 2157/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | EGLN1 12/4885BBOX1 1285/4885FTO 1983/4885 |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | EGLN1 10/4885BBOX1 1985/4885FTO 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.